Health Trials

Refractory Malignant Solid Tumors

2

Review clinical trials related to Refractory Malignant Solid Tumors. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

This study aims to investigate the safety and efficacy of the IL-22BP in patients with refractory malignant solid tumors.

Participants needed: 6
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: West China HospitalUpdated: Apr 13, 2026Locations: 2
Eligibility criteria

Male or female patients: aged ≥ 18 years old and ≤ 70 years old; [+7]

Have participated in other drug clinical trials within 4 weeks; [+11]

Read more
Status: Recruiting

A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

This study aims to investigate the safety and efficacy of the IL-22BP/LNP compound in patients with refractory malignant solid tumors, such as advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, and malignant melanoma, who have failed second-line treatment, have advanced recurrence or metastatic malignant solid tumors.

Participants needed: 6
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Xingchen PengUpdated: Dec 29, 2025Locations: 1
Eligibility criteria

Male or female patients: aged ≥ 18 years old and ≤ 70 years old; [+7]

Have participated in other drug clinical trials within 4 weeks; [+11]

Read more